Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

BACKGROUND The incidence of colorectal cancer (CRC) in younger patients is rising, mostly due to tumors in the descending colon and rectum. Therefore, we aimed to explore the molecular differences of left-sided CRC between younger (≤45 years) and older patients (≥65). SUBJECTS, MATERIALS, AND METHODS In total, 1,126 CRC tumor samples from the splenic flexure to (and including) the rectum were examined by next-generation sequencing (NGS), immunohistochemistry, and in situ hybridization. Microsatellite instability (MSI) and tumor mutational burden (TMB) were assessed by NGS. RESULTS Younger patients (n = 350), when compared with older patients (n = 776), showed higher mutation rates in genes associated with cancer-predisposing syndromes (e.g., Lynch syndrome), such as MSH6 (4.8% vs. 1.2%, p = .005), MSH2 (2.7% vs. 0.0%, p = .004), POLE (1.6% vs. 0.0%, p = .008), NF1 (5.9% vs. 0.5%, p < .001), SMAD4 (14.3% vs. 8.3%, p = .024), and BRCA2 (3.7% vs. 0.5%, p = .002). Genes involved in histone modification were also significantly more mutated: KDM5C (1.9% vs. 0%, p = .036), KMT2A (1.1% vs. 0%, p = .033), KMT2C (1.6% vs. 0%, p = .031), KMT2D (3.8% vs. 0.7%, p = .005), and SETD2 (3.2% vs. 0.9%, p = .039). Finally, TMB-high (9.7% vs. 2.8%, p < .001) and MSI-high (MSI-H; 8.1% vs. 1.9%, p = .009) were more frequent in younger patients. CONCLUSION Our findings highlight the importance of genetic counseling and screening in younger CRC patients. MSI-H and TMB-high tumors could benefit from immune-checkpoint inhibitors, now approved for the treatment of MSI-H/deficient mismatch repair metastatic CRC patients. Finally, histone modifiers could serve as a new promising therapeutic target. With confirmatory studies, these results may influence our approach to younger adults with CRC. IMPLICATIONS FOR PRACTICE The increasing rate of colorectal cancers (CRC), primarily distal tumors, among young adults poses a global health issue. This study investigates the molecular differences between younger (≤45 years old) and older (≥65) adults with left-sided CRCs. Younger patients more frequently harbor mutations in genes associated with cancer-predisposing syndromes. Higher rates of microsatellite instability-high and tumor mutational burden-high tumors occur in younger patients, who could benefit from immune-checkpoint inhibitors. Finally, histone modifiers are more frequently mutated in younger patients and could serve as a new promising therapeutic target. This study provides new insights into mutations that may guide development of novel tailored therapy in younger CRC patients.

[1]  K. Moorthy,et al.  Fusobacterium species are distinctly associated with patients with Lynch syndrome colorectal cancer , 2020, ANZ journal of surgery.

[2]  John L Marshall,et al.  Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers , 2018, Molecular Cancer Research.

[3]  J. Ferlay,et al.  Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. , 2017, The Lancet. Oncology.

[4]  P. Philip,et al.  Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers , 2017, Oncotarget.

[5]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[6]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[7]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Philip S Rosenberg,et al.  Colorectal Cancer Incidence Patterns in the United States, 1974–2013 , 2017, Journal of the National Cancer Institute.

[9]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[10]  M. Bertagnolli,et al.  Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). , 2017 .

[11]  J. Marshall,et al.  The Growing Challenge of Young Adults With Colorectal Cancer. , 2017, Oncology.

[12]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[13]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[14]  P. Goodfellow,et al.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer , 2017, JAMA oncology.

[15]  S. Barni,et al.  Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[16]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[17]  E. Frangou,et al.  Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. , 2016, The lancet. Gastroenterology & hepatology.

[18]  Z. Zeng,et al.  Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. , 2016, Journal of pediatric surgery.

[19]  Ge Zhang,et al.  Therapeutic Advances in Gastroenterology Targeting Histone Methylation for Colorectal Cancer , 2022 .

[20]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[21]  M. Berger,et al.  Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Shibata,et al.  Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers , 2016, Cancer.

[23]  W. Garrett,et al.  Gut Microbiota, Inflammation, and Colorectal Cancer. , 2016, Annual review of microbiology.

[24]  V. Torri,et al.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[25]  S. Hendren,et al.  Colorectal cancer outcomes and treatment patterns in patients too young for average‐risk screening , 2016, Cancer.

[26]  D. Roder,et al.  Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. , 2016, Clinical colorectal cancer.

[27]  L. Boardman,et al.  Clinical and molecular features of young-onset colorectal cancer. , 2016, World journal of gastroenterology.

[28]  J. Marshall,et al.  Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome. , 2016 .

[29]  L. Reggiani Bonetti,et al.  Molecular Features and Methylation Status in Early Onset (≤40 Years) Colorectal Cancer: A Population Based, Case-Control Study , 2015, Gastroenterology research and practice.

[30]  H. Lenz,et al.  Primary tumor location as a prognostic factor in metastatic colorectal cancer. , 2015, Journal of the National Cancer Institute.

[31]  Rui Wang,et al.  Clinicopathological Features and Survival Outcomes of Colorectal Cancer in Young Versus Elderly , 2015, Medicine.

[32]  C. Underhill,et al.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. , 2015, European journal of cancer.

[33]  F. Sinicrope,et al.  Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer , 2015, Current Treatment Options in Oncology.

[34]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[35]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[36]  J. García,et al.  Early-onset colorectal cancer: a separate subset of colorectal cancer. , 2014, World journal of gastroenterology.

[37]  A. Martayan,et al.  Early-onset colorectal cancer: a sporadic or inherited disease? , 2014, World journal of gastroenterology.

[38]  Hongtu Zheng,et al.  Pathological Features and Survival Outcomes of Young Patients with Operable Colon Cancer: Are They Homogeneous? , 2014, PloS one.

[39]  D. Ahnen,et al.  The increasing incidence of young-onset colorectal cancer: a call to action. , 2014, Mayo Clinic proceedings.

[40]  B. Person,et al.  Diagnosis of colon cancer differs in younger versus older patients despite similar complaints. , 2013, The Israel Medical Association journal : IMAJ.

[41]  Ian Tomlinson,et al.  Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers , 2013, The Journal of pathology.

[42]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[43]  C. Boland,et al.  A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer , 2012, PloS one.

[44]  A. Papavassiliou,et al.  Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. , 2012, The international journal of biochemistry & cell biology.

[45]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[46]  C. Boland,et al.  Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  A. Carothers,et al.  Evidence for an age‐related influence of microsatellite instability on colorectal cancer survival , 2002, International journal of cancer.

[48]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[49]  S. Cantor,et al.  Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. , 2015, JAMA surgery.